Novo Nordisk Launches First and Only Multi-Month Subscription Program for FDA-Approved Wegovy, Offering Savings of up to $1,200/year

Tuesday, March 31, 2026 – Wednesday, April 1 - PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers...








